{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:36:00Z","timestamp":1770892560208,"version":"3.50.1"},"reference-count":81,"publisher":"Informa UK Limited","issue":"3","funder":[{"name":"Belgian Fonds de la recherche Scientifique"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anti-infective Therapy"],"published-print":{"date-parts":[[2016,3,3]]},"DOI":"10.1586\/14787210.2016.1138857","type":"journal-article","created":{"date-parts":[[2016,1,6]],"date-time":"2016-01-06T05:48:03Z","timestamp":1452059283000},"page":"311-324","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":16,"title":["The role of solithromycin in the management of bacterial community-acquired pneumonia"],"prefix":"10.1586","volume":"14","author":[{"given":"Fran\u00e7oise","family":"Van Bambeke","sequence":"first","affiliation":[{"name":",","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"Tulkens","sequence":"additional","affiliation":[{"name":",","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2016,2,5]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61682-2"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12461"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2014.07.021"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1086\/425615"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60733-4"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2009.129502"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2013.11.2710"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e32835ebc6d"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-014-2067-1"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-012-1778-4"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00110911"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2011-200630"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/trstmh\/tru058"},{"key":"e_1_3_3_16_1","doi-asserted-by":"crossref","first-page":"ITC1","DOI":"10.7326\/AITC201510060","article-title":"Community-Acquired Pneumonia","volume":"163","author":"Niederman MS","year":"2015","unstructured":"Niederman MS. Community-Acquired Pneumonia. Ann Intern Med. 2015;163:ITC1.","journal-title":"Ann Intern Med"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2015.1060125"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1086\/511159"},{"issue":"6","key":"e_1_3_3_19_1","first-page":"E1E59","article-title":"Guidelines for the management of adult lower respiratory tract infections\u2013full version","volume":"17","author":"Woodhead M","year":"2011","unstructured":"Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections\u2013full version. Clin Microbiol Infect. 2011;17(Suppl 6):E1E59.","journal-title":"Clin Microbiol Infect"},{"key":"e_1_3_3_20_1","doi-asserted-by":"crossref","first-page":"e000091","DOI":"10.1136\/bmjresp-2015-000091","article-title":"British Thoracic Society community acquired pneumonia guideline and the NICE pneumonia guideline: how they fit together","volume":"2","author":"Lim WS","year":"2015","unstructured":"Lim WS, Smith DL, Wise MP, et al. British Thoracic Society community acquired pneumonia guideline and the NICE pneumonia guideline: how they fit together. BMJ Open Respir Res. 2015;2:e000091.","journal-title":"BMJ Open Respir Res"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S75412"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S56616"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-75613-4_11"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05658-11"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000652"},{"issue":"3","key":"e_1_3_3_26_1","first-page":"S187S193","article-title":"AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States","volume":"55","author":"Pfaller MA","year":"2012","unstructured":"Pfaller MA, Farrell DJ, Sader HS, et al. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. Clin Infect Dis. 2012;55(Suppl 3):S187S193.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt332"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02597-14"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01684-08"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767160-00005"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2006.06.008"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/1755-5922.12054"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr159"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12077"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-015-0507-4"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2012.03838.x"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201502-0212OC"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr520"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2015.05.003"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.4887"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23312"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2014.935470"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.2.267"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00840-10"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00860-10"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02316-12"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2013.10.013"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.01.026"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04568-14"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.08.021"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01343-09"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01639-13"},{"key":"e_1_3_3_57_1","unstructured":"Farrell DJ Flamm RK Sader HS et al. Activity of solithromycin tested against pathogens associated with community-acquired bacterial pneumonia: Global surveillance results for 2014. 55th Interescience Conference on Antimicrobial Agents and Chemotherapy (American Society for Microbiology); 2015; September 17\u201321; San Diego CA. Poster no. C622."},{"key":"e_1_3_3_58_1","unstructured":"Tulkens PM Van Bambeke F Vandevelde NM et al. In vitro susceptibility of S. pneumoniae to solithromycin (SOL) in collections with an elevated proportion of isolates resistant to levofloxacin (LVX) and moxifloxacin (MXF). 25th European Congress of Clinical Microbiology and Infectious Diseases (European Society of Clinical Microbiology and Infectious Diseases); 2015; April 25\u201328; Copenhagen. Poster no. EV0153."},{"key":"e_1_3_3_59_1","unstructured":"Magnet S Morrissey I Fernandes P et al. Assessment of the bactericidal activity of solithromycin (CEM-101) against Streptococcus pneumoniae with known macrolide-resistance mechanism and serotype. 55th Interescience Conference on Antimicrobial Agents and Chemotherapy (American Society for Microbiology); 2015; September 17\u201321; San Diego CA. Poster no. C550"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01858-13"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00203-09"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01429-10"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00766-12"},{"key":"e_1_3_3_67_1","unstructured":"Okusanya OO Bhavnani SM Forrest A et al. Population Pharmacokinetic (PPK) and Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment (TA) Analyses for Solithromycin (SOL CEM-101) to Support Intravenous (IV). 52d Interscience Conference on Antimicrobial Agents and Chemotherapy (American Society for Microbiology); 2012; September 9\u201312; San Francisco CA. Poster no. A1269."},{"key":"e_1_3_3_68_1","unstructured":"Okusanya OO Bhavnani SM Forrest A et al. Pharmacokinetic-Pharmacodynamic target attainment analysis supporting Solithromycin (CEM-101) Phase 2 dose selection. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (American Society for Microbiology); 2010; September 12\u201315; Boston MA. Poster no. A1A692."},{"key":"e_1_3_3_69_1","unstructured":"Schranz J Clark K Marion A et al. A Phase 1 trial to evaluate the safety and pharmacokinetics of single doses of intravenous (IV) solithromycin (CEM-101) in healthy adult subjects. 21th European Congress of Clinical Microbiology and Infectious Diseases (European Society of Microbiology and Infectious Diseases) & 27th International Congress of Chemotherapy (International Society of Chemotherapy); 2011; May 7\u201310; Milano. Poster no. O95."},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04652-14"},{"key":"e_1_3_3_71_1","unstructured":"Andes DR Okusanya OO Forrest A et al. Pharmacokinetic-Pharmacodynamic (PK-PD) analysis of Solithromycin against Streptococcus pneumoniae using data from a murine-lung infection model. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (American Society for Microbiology); 2010; September 12\u201315; Boston. Poster no. A1A688."},{"key":"e_1_3_3_72_1","unstructured":"Gonzales D Palazzi D Bhattacharya-Mithal L et al. Pharmacokinetics and safety of solithromycin in adolescents with suspected or confirmed bacterial infection. Meeting of the Pediatric Academic Societies Meeting; 2015; April 25\u201328; San Diego CA. Poster no. P340."},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.112.200733"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12187"},{"key":"e_1_3_3_75_1","unstructured":"Darpo B Philip S Zhou M et al. Solithromycin a 4th generation macrolide and the 1st fluoroketolide does not prolong the QTc interval: results of a definitive QT study. 25th European Congress of Clinical Microbiology and Infectious Diseases (European Society of Microbiology and Infectious Diseases); 2015; April 25\u201328; Copenhagen. Poster no. LBEV0081a."},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00197-13"},{"key":"e_1_3_3_78_1","unstructured":"Chochua S Sheets A Keedy K et al. Prevalence of pneumococcal serotypes in adults enrolled in a Phase 3 trial that evaluated the efficacy and safety of oral solithromycin (CEM-101) versus moxifloxacin in adults with CABP. 55th Interescience Conference on Antimicrobial Agents and Chemotherapy (American Society for Microbiology) 2015; September 17\u201321; San Diego CA. Poster no. L1274."},{"key":"e_1_3_3_79_1","unstructured":"Oldach D Metev H Mykiertiul A et al. Characterization of Mycoplasma pneumoniae infection and outcomes in the Solitaire-Oral Global Phase 3 Clinical Trial for Solithromycin. ID Week (Infectious Diseases Society of America) 2012; September 17\u201321; San Francisco CA. Poster no. 893"},{"key":"e_1_3_3_80_1","doi-asserted-by":"crossref","unstructured":"Oldach D Barrera CM Luna C et al. Oral solithromycin has a favorable profile versus oral moxifloxacin for treatment of adult community-acquired bacterial pneumonia (CABP) in elderly patients and those with COPD or asthma. 25th Annual Congress of European Respiratory Society (European Respiratory Society); 2015; September 26\u201330; Amsterdam. Poster no. PA2655.","DOI":"10.1183\/13993003.congress-2015.PA2655"},{"key":"e_1_3_3_81_1","unstructured":"Oldach D Barrera CM Metev H et al. Oral solithromycin versus oral moxifloxacin for treatment of adult community-acquired bacterial pneumonia (CABP): results of the global Phase 3 trial solitaire oral. American Thoracic Society Conference (American Thoracic Society); 2015; May 15\u201320; Poster no. A6424."},{"key":"e_1_3_3_82_1","unstructured":"The top 10 causes of death. The World Health Organization [Internet]. Geneva: Media Center- Fact sheets. 2014. [cited 2015 Oct 25]. Available from: http:\/\/www.who.int\/mediacentre\/factsheets\/fs310\/en\/index1.html."},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60222-6"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61689-4"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.954036"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.06300.x"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)70057-5"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00188-5"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70949-1"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200932050-00001"},{"key":"e_1_3_3_91_1","unstructured":"Carbonnelle S Lismond A Van Bambeke F et al. Analysis of guidelines for treatment of Community acquired pneumonia (CAP) in outpatients. 26th International Conference on Chemotherapy (International Society of Chemotherapy); 2009; June 18\u201321; Toronto ON. Poster no. 315"}],"container-title":["Expert Review of Anti-infective Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/14787210.2016.1138857","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:45:36Z","timestamp":1770889536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1586\/14787210.2016.1138857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,5]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3,3]]}},"alternative-id":["10.1586\/14787210.2016.1138857"],"URL":"https:\/\/doi.org\/10.1586\/14787210.2016.1138857","relation":{},"ISSN":["1478-7210","1744-8336"],"issn-type":[{"value":"1478-7210","type":"print"},{"value":"1744-8336","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-11-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-01-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-02-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}